As soon as the results of the tenth batch of centralized procurement of drugs organized by the state were announced, some domestically produced generic drugs selected at low prices attracted attention, especially aspirin enteric coated tablets with a minimum price of 3 cents per tablet. A netizen raised a question: "Do you dare to take a medicine that costs 3 cents per pill?" The question is a bit sharp, but understandable. For patients and their families, the decrease in drug prices and the reduction in the burden of medical treatment are certainly welcome, but will too low prices affect the quality of drugs? After all, in order for a company to make money, it is impossible to "lose money and make noise". It seems that the key issue lies in whether the winning bid price can cover the production cost. In other words, it means whether a company can still make a profit by selling drugs at such a price. The response of the selected pharmaceutical companies to this is that they can make profits. There are several reasons for this: the production process of aspirin enteric coated tablets is very mature, and the raw material prices are not high; Enterprises effectively control costs through automation, large-scale production, and other methods, and the selected product is a large box of 60 pieces, which further reduces packaging losses; The scale of centralized procurement is large, and with a huge demand of billions of pieces per year nationwide, it can achieve small profits but high sales. The statement of the enterprise has also been partially confirmed. Some media have searched a domestic chemical service platform and found that the market price of aspirin raw materials is around 30 yuan per kilogram, which is equivalent to a raw material cost of 0.003 yuan per 100 milligrams tablet, or 3 cents. The purchase price for large quantities is even lower. If the market supply can remain stable, companies do have the conditions to control costs. In addition, the national regulatory efforts have always been strong for enterprises and drugs selected through centralized procurement. According to the relevant person in charge of the National Medical Products Administration, 100% full coverage of production enterprise inspection and selected variety sampling inspection will be implemented for the selected drugs and equipment to ensure that the selected products are "reduced in price without compromising quality". From this perspective, enterprises can obtain reasonable returns by controlling production costs and expanding market size, coupled with strict external supervision, there is no reason to lower quality. Quality is the bottom line of centralized procurement of drugs, and no one can touch it at any time. The low-priced aspirin enteric coated tablets and other generic drugs selected this time will be launched in April this year. This means that patients will be able to use this batch of drugs in about 3 months. To ensure that patients' medication is foolproof, all parties should fulfill their duties, strictly control at all levels, and maintain the bottom line of quality. Enterprises should strictly conduct self-examination and self inspection. In the preparation stage, the raw and auxiliary materials provided by upstream enterprises must be inspected according to the strictest standards, and only after passing the inspection can they be sent to the production line. In the production stage, it is necessary to strictly follow the process and environmental requirements, implement and refine every rule and regulation, and do a good job in equipment management and risk assessment. In the quality inspection stage, it is necessary to improve the testing methods, avoid human influence, enhance the accuracy of testing, and never allow any problematic drugs to flow out of the company's doors. Regulatory authorities should strictly supervise enterprises. Especially for generic drugs produced by selected enterprises, strict evaluation of quality and efficacy consistency should be carried out in accordance with the same standards as the original drug. Not only do we adhere to strict standards during the review and approval process, but we also insist on full coverage supervision even after the drug has been approved for marketing. We require companies to strictly follow the production process used in the application for consistency evaluation, and re approve major changes. Of course, while strictly supervising enterprises, we should also assist and serve them. Fluctuations in raw material prices and supply, as well as changes in equipment and environment, can all pose certain risks to production. It is suggested that relevant departments optimize the drug regulatory model, shifting from a "post disposal" to a "pre prevention" approach, to help enterprises eliminate risks and ensure production safety. (New Society)